利妥昔单抗成功治疗血管免疫母细胞性T细胞淋巴瘤。
Successful treatment with rituximab for angioimmunoblastic T-cell lymphoma.
作者信息
Kasahara Hidenori, Kakimoto Tsunayuki, Saito Hideaki, Akuta Keigo, Yamamoto Kazutaka, Ujiie Hidetoshi, Sugahara Hiroyuki, Hoshida Yoshihiko, Sakoda Hiroto
机构信息
Sumitomo Hospital, Department of Hematology, Osaka, Japan.
Rinku General Medical Center, Department of Hematology, Osaka, Japan.
出版信息
Leuk Res Rep. 2013 May 1;2(1):36-8. doi: 10.1016/j.lrr.2013.03.001. eCollection 2013.
We experienced a patient with angioimmunoblastic T-cell lymphoma (AITL) without Epstein-Barr virus-positive B (EBV-B) cells at initial presentation who progressed to AITL with expansion of EBV-B cells at relapse. Based on the results of repeated biopsy, the patient was successfully treated with rituximab in combination with chemotherapy at relapse. A repeat biopsy may be necessary to determine the optimum therapeutic strategy at relapse, particularly for patients with suspected expansion of B cell and/or EBV-B cells. Although a recent report found no significant prognostic advantage of rituximab, it is one of the active drugs for selected patients with AITL.
我们遇到一名血管免疫母细胞性T细胞淋巴瘤（AITL）患者，初诊时无爱泼斯坦-巴尔病毒阳性B（EBV-B）细胞，复发时进展为伴有EBV-B细胞扩增的AITL。根据重复活检结果，该患者在复发时接受利妥昔单抗联合化疗成功治疗。对于复发时确定最佳治疗策略，尤其是怀疑B细胞和/或EBV-B细胞扩增的患者，重复活检可能是必要的。尽管最近一份报告发现利妥昔单抗没有显著的预后优势，但它是部分AITL患者的有效药物之一。
Zotero 插件